Kodiak Sciences Chief Financial Officer John Borgeson Receives Stock Option Grant

Executive Compensation Structure at Kodiak Sciences

Kodiak Sciences, a NASDAQ-listed biopharmaceutical company specializing in treatments for retinal diseases, disclosed the equity grant awarded to its Chief Financial Officer as part of ongoing executive compensation arrangements. John A. Borgeson holds the position of Chief Financial Officer and is based at the company's headquarters located at 1250 Page Mill Road in Palo Alto, California. The stock option award represents a component of equity-based compensation commonly utilized in the pharmaceutical and biotechnology sectors to align executive incentives with shareholder value creation over extended time horizons.

Equity grants to executive officers in the biopharmaceutical industry typically include vesting schedules designed to encourage long-term retention and performance. The structure disclosed in this regulatory update reflects standard practice among NASDAQ-listed life sciences companies, where multi-year vesting encourages executives to remain committed to the organization's strategic objectives and clinical development milestones. The conditional nature of Borgeson's vesting schedule, which depends on his continuous service with Kodiak Sciences, demonstrates the company's approach to retention-based compensation design.

Details of the July 2026 Option Grant

The stock option grant awarded to Chief Financial Officer Borgeson provides the right to purchase 66,500 shares of Kodiak Sciences common stock at a fixed exercise price of $42.42 per share. The options carry an expiration date of July 14, 2036, providing a ten-year window during which the executive may exercise the grant. The transaction date for the grant was reported as July 15, 2026, marking the formal issuance of the equity incentive. This pricing reflects the company's valuation methodology at the time of grant, which typically uses the fair market value of the company's common stock on the grant date.

According to the regulatory update, the options are structured with a staged vesting approach designed to encourage sustained commitment to the organization. One-forty-eighth of the total grant vests one month after July 1, 2026, establishing an initial vesting milestone. Following this initial tranche, the remaining shares vest in 47 successive equal monthly installments thereafter, contingent on the reporting person's continuous service as defined by Kodiak Sciences' 2018 Equity Incentive Plan. This schedule results in full vesting approximately four years following the grant date, a timeframe commonly employed to align executive interests with medium-to-long-term business performance.

Kodiak Sciences' Business Operations and Market Position

Kodiak Sciences operates as a biopharmaceutical company with a focused pipeline addressing retinal diseases, an area representing significant clinical need and commercial opportunity within ophthalmology. The company's approach emphasizes development of therapies targeting degenerative and inflammatory conditions affecting the retina, a segment of the pharmaceutical market characterized by ongoing innovation and high barriers to entry. As a NASDAQ-listed entity, Kodiak Sciences operates under comprehensive public company disclosure and governance requirements that ensure transparent communication with investors regarding material business developments and executive compensation practices.

The biopharmaceutical sector, particularly companies focused on specialty disease areas such as retinal conditions, typically relies on equity-based compensation to attract and retain experienced financial leadership during extended development and commercialization phases. Executive retention in life sciences companies proves critical during clinical trial programs, regulatory submissions, and potential product launches, periods during which financial expertise becomes essential for capital planning, investor relations, and strategic decision-making. The award to Chief Financial Officer Borgeson reflects the company's strategy to maintain experienced financial leadership during its operational phases.

Vesting Schedule and Service Requirements

The vesting arrangement disclosed in the regulatory update incorporates a performance and tenure-based structure typical of equity compensation in public biotechnology companies. The initial vesting milestone requires only the passage of one month from the July 1, 2026 reference date, releasing one-forty-eighth of the granted options to the executive. The remaining 47 equal monthly installments distribute the substantial majority of the grant across the subsequent 47 months, creating a continuous incentive structure that extends beyond typical single-year vesting periods commonly observed in other corporate sectors.

Vesting remains contingent on John A. Borgeson's maintenance of "Continuous Service" status as defined within Kodiak Sciences' 2018 Equity Incentive Plan. This language protects the company's interests by ensuring that the equity grant benefits only executives who remain employed and engaged with the organization throughout the vesting period. The monthly installment structure distributes risk and incentive across an extended timeframe, potentially reducing the concentration of equity value realization in any single period and aligning executive interests with the company's ongoing operational performance.

Regulatory Disclosure and Beneficial Ownership Reporting

The regulatory update filed on July 17, 2026, represents John A. Borgeson's formal disclosure of beneficial ownership changes resulting from the stock option grant, submitted pursuant to Section 16(a) of the Securities Exchange Act of 1934. Such disclosures serve as mechanisms ensuring public transparency regarding changes in executive holdings and potential conflicts of interest. The report indicates that Borgeson held direct beneficial ownership of 66,500 option shares following the reported transaction, with the options recorded as derivative securities in the regulatory filing structure.

The disclosure process requires executives and substantial shareholders to report transactions and ownership changes within specified timeframes, enabling investors and regulators to maintain oversight of material ownership developments. The filing was executed by David Peinsipp, identified as attorney-in-fact for John Borgeson, on July 17, 2026, providing dated authentication of the reported information. This third-party execution signature arrangement represents a standard administrative practice in corporate governance and regulatory compliance procedures.

Equity Incentive Plans in Biopharmaceutical Companies

Kodiak Sciences' utilization of the 2018 Equity Incentive Plan as the framework for this executive stock option grant reflects industry-standard practice among publicly traded biopharmaceutical companies. Equity incentive plans serve multiple strategic purposes within life sciences organizations, including executive recruitment, retention of key personnel during extended development cycles, and alignment of management incentives with shareholder value creation. The 2018 plan designation suggests that the company maintains a contemporary framework for equity-based compensation decisions, updated to reflect current regulatory requirements and market practices.

Within the biopharmaceutical sector, equity grants to executives typically carry longer vesting periods than those common in other industries, acknowledging the extended timelines required for drug development, clinical trials, and regulatory approval processes. The approximately four-year vesting schedule for Borgeson's grant aligns with typical practices for senior financial officers in companies navigating clinical development and commercialization phases. Such arrangements demonstrate recognition that significant value creation in pharmaceutical companies often extends across multiple years of operational commitment and strategic execution.

Exercise Price and Share Valuation Considerations

The exercise price of $42.42 per share established for the July 2026 option grant reflects the pricing methodology employed by Kodiak Sciences at the time of grant issuance. The company did not disclose the specific valuation or fair market value determination procedures used to establish this exercise price in the regulatory filing. Exercise prices in equity compensation arrangements typically anchor to the fair market value of company stock on the grant date, a standard practice designed to satisfy tax and accounting requirements governing equity-based compensation in publicly traded companies.

The ten-year exercise window provided by the option grant, extending from July 15, 2026 to July 14, 2036, creates an extended period during which Chief Financial Officer Borgeson may choose to exercise his options and acquire underlying shares of Kodiak Sciences common stock. The extended timeline allows flexibility in exercise decisions based on future developments affecting the company's valuation, market conditions, and the executive's personal financial planning. Investors monitoring executive compensation may observe exercise activity in future periods as vesting milestones are achieved and market conditions evolve.

Insider Trading Considerations and Reporting Obligations

The regulatory update filed by John A. Borgeson constitutes an insider transaction disclosure, reflecting the company's and the executive's obligations under federal securities laws governing publicly traded companies. Chief Financial Officer status creates automatic reporting obligations under Section 16 of the Securities Exchange Act, requiring disclosure of transactions and beneficial ownership changes within specified timeframes following transaction completion. These reporting requirements serve to prevent potential insider trading abuses and ensure transparent markets for Kodiak Sciences securities.

The form 4 regulatory update filed on July 17, 2026, documented the July 15, 2026 transaction date with immediate disclosure to the market and regulatory authorities. The immediate share price impact was not clear from available public information contained in the regulatory filing itself. Investors tracking executive compensation and insider holdings may monitor subsequent filings for evidence of exercise activity or additional equity grants that might signal management confidence in the company's strategic direction or clinical development progress.